MEOBF OTC

Mesoblast Limited, an Australian biopharmaceutical company established in Melbourne in 2004, specializes in the development and global commercialization of allogeneic cellular medicines. With operations spanning the United States, Australia, Singapore, the United Kingdom, and Switzerland, the firm leverages a proprietary regenerative medicine platform based on specialized mesenchymal lineage cells. This technology underpins treatments for a wide spectrum of conditions, including cardiovascular, spinal orthopedic, oncological, hematological, immune-mediated, and inflammatory diseases. The company's advanced pipeline includes several products in Phase III clinical trials. Remestemcel-L is being investigated for steroid-refractory acute graft versus host disease (GvHD) and acute respiratory distress syndrome (ARDS) linked to COVID-19 infection. Rexlemestrocel-L is progressing for advanced chronic heart failure, while MPC-06-ID targets chronic low back pain resulting from degenerative disc disease. Additionally, Mesoblast is developing MPC-300-IV for biologic-refractory rheumatoid arthritis and diabetic nephropathy. Strategic partnerships are integral to Mesoblast's operations. The company collaborates with Tasly Pharmaceutical Group to market MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China. A partnership with JCR Pharmaceuticals Co. Ltd. focuses on wound healing for patients with epidermolysis bullosa. Furthermore, Mesoblast works with Grünenthal to develop and commercialize cell therapy for chronic low back pain.